378 related articles for article (PubMed ID: 14605627)
1. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
Wu PC; Langerman A; Ryan CW; Hart J; Swiger S; Posner MC
Surgery; 2003 Oct; 134(4):656-65; discussion 665-6. PubMed ID: 14605627
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
3. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST).
Rutkowski P; Nyckowski P; Grzesiakowska U; Nowecki ZI; Nasierowska-Guttmejer A; Pienkowski A; Dudek K; Krawczyk M; Ruka W
Neoplasma; 2003; 50(6):438-42. PubMed ID: 14689066
[TBL] [Abstract][Full Text] [Related]
4. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
5. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
6. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
7. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
Gold JS; Dematteo RP
Ann Surg; 2006 Aug; 244(2):176-84. PubMed ID: 16858179
[TBL] [Abstract][Full Text] [Related]
8. Giant malignant gastrointestinal stromal tumors: recurrence and effects of treatment with STI-571.
Chen TW; Liu HD; Shyu RY; Yu JC; Shih ML; Chang TM; Hsieh CB
World J Gastroenterol; 2005 Jan; 11(2):260-3. PubMed ID: 15633227
[TBL] [Abstract][Full Text] [Related]
9. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
[TBL] [Abstract][Full Text] [Related]
10. Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.
Shen C; Chen H; Yin Y; Chen J; Zhang B; Chen Z; Chen J
Clinics (Sao Paulo); 2014 Nov; 69(11):758-62. PubMed ID: 25518034
[TBL] [Abstract][Full Text] [Related]
11. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
Demetri GD
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
[TBL] [Abstract][Full Text] [Related]
12. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal stromal tumors (GIST): a single center experience.
Kostka R; Gürlich R; Koldová L
Acta Chir Belg; 2012 Jan; 112(1):33-9. PubMed ID: 22442907
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal stromal tumors: diagnosis and treatment.
Acín-Gándara D; Pereira-Pérez F; Castaño-Pascual A; Durán-Poveda M; Antequera-Pérez A; Miliani-Molina C
Cir Cir; 2012; 80(1):44-51. PubMed ID: 22472152
[TBL] [Abstract][Full Text] [Related]
15. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
[TBL] [Abstract][Full Text] [Related]
16. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal stromal tumors: chemotherapy and imatinib.
Muler JH; Baker L; Zalupski MM
Curr Oncol Rep; 2002 Nov; 4(6):499-503. PubMed ID: 12354362
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?
Scaife CL; Hunt KK; Patel SR; Benjamin RS; Burgess MA; Chen LL; Trent J; Raymond AK; Cormier JN; Pisters PW; Pollock RE; Feig BW
Am J Surg; 2003 Dec; 186(6):665-9. PubMed ID: 14672776
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of gastrointestinal stromal tumors: before and after STI-571.
Dematteo RP; Heinrich MC; El-Rifai WM; Demetri G
Hum Pathol; 2002 May; 33(5):466-77. PubMed ID: 12094371
[TBL] [Abstract][Full Text] [Related]
20. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]